(Albany, United States) As per DelveInsight’s assessment, globally, the Prostate Cancer pipeline constitutes 200+ key companies continuously working towards developing 200+ Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Prostate Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Prostate Cancer clinical trials studies, Prostate Cancer NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the Prostate Cancer pipeline treatment landscape of the report, click here @ Prostate Cancer Pipeline Outlook
Key Takeaways from the Prostate Cancer Pipeline Report
- DelveInsight’s Prostate Cancer Pipeline analysis depicts a robust space with 200+ active players working to develop 200+ pipeline treatment therapies.
- The leading Prostate Cancer Companies working in the market include Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio Inc, and others
- Promising Prostate Cancer Pipeline in the various stages of development include Capivasertib, Enzalutamide, Abiraterone, Digoxin, Rosuvastatin, Flutamide, Androgen Deprivation Therapy, rhPSMA-7.3 (18F) Injection, olaparib, abiraterone acetate, AGS-1C4D4, SRF617, and others.
- On April 2023, AstraZeneca announced a study of phase 3 clinical trials for olaparib and abiraterone acetate. The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.
- On April 2023, Surface Oncology announced a study of phase 2 clinical trials for SRF617, etrumadenant, and zimberelimab. This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).
Prostate Cancer Overview
The prostate is a small walnut shaped gland in the pelvis of men. It is located next to the bladder and can be examined by getting a digital rectal exam. Prostate Cancer is a form of cancer that develops in the prostate gland. It is the second-leading cause of cancer deaths for men in the U.S.
To explore more information on the latest breakthroughs in the Prostate Cancer Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight
Prostate Cancer Emerging Drugs Profile
- Pembrolizumab: Merck & Co
- Talazoparib: Pfizer
- ODM-208: Orion
- ZEN 3694: Zenith Epigenetics
- EPI-7386: ESSA Pharma
Prostate Cancer Pipeline Therapeutics Assessment
There are approx. 200+ key companies which are developing the therapies for Prostate Cancer. The companies which have their Prostate Cancer drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.
Request a sample and discover the recent advances in Prostate Cancer Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight
Prostate Cancer Drugs and Companies
- Capivasertib: AstraZeneca
- Enzalutamide: Parexel
- enzalutamide: Astellas Pharma
- Digoxin: Pfizer
Prostate Cancer Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Prostate Cancer Therapeutics Market include-
Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio Inc, and others
Dive deep into rich insights for drugs for Prostate Cancer Pipeline, click here for Prostate Cancer Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight
Scope of the Prostate Cancer Pipeline Report
- Coverage- Global
- Prostate Cancer Companies- Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio Inc, and others
- Prostate Cancer Therapies- Capivasertib, Enzalutamide, Abiraterone, Digoxin, Rosuvastatin, Flutamide, Androgen Deprivation Therapy, rhPSMA-7.3 (18F) Injection, olaparib, abiraterone acetate, AGS-1C4D4, SRF617, and others.
- Prostate Cancer Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Prostate Cancer Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight
Table of Content
- Introduction
- Executive Summary
- Prostate Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- Pembrolizumab: Merck & Co
- Drug profiles in the detailed report….
- Mid Stage Products (Phase II)
- ODM-208: Orion Pharma
- Drug profiles in the detailed report….
- Early Stage Products (Phase I)
- EPI 7386: ESSA Pharma
- Drug profiles in the detailed report….
- Preclinical and Discovery Products
- Drug name: Company name
- Drug profiles in the detailed report…
- Inactive Products
- Prostate Cancer Key Companies
- Prostate Cancer Key Products
- Prostate Cancer- Unmet Needs
- Prostate Cancer- Market Drivers and Barriers
- Prostate Cancer- Future Perspectives and Conclusion
- Prostate Cancer Analyst Views
- Prostate Cancer Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services